RYTM
HealthcareRhythm Pharmaceuticals, Inc. · Biotechnology · $6B
What is Rhythm Pharmaceuticals, Inc.?
Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare genetic diseases of obesity. Headquartered in Boston, Massachusetts, the company has built its pipeline around a targeted approach to the melanocortin pathway.
Rhythm Pharmaceuticals develops and commercializes treatments for rare, genetically driven forms of obesity — conditions that are often unresponsive to conventional weight-loss therapies. Its commercial product, IMCIVREE, targets the melanocortin-4 receptor pathway, addressing specific genetic deficiencies that cause severe obesity from childhood. Beyond its approved indication, the company is advancing setmelanotide through clinical trials for a broader range of MC4R-pathway disorders, aiming to expand its addressable patient population over time.
Rhythm Pharmaceuticals was founded in 2008 and is headquartered in Boston, Massachusetts.
- IMCIVREE — approved melanocortin-4 receptor agonist for rare genetic obesity
- Setmelanotide — pipeline therapy in Phase II for multiple MC4R-pathway disorders
- Collaborative research with the Clinical Registry Investigating Bardet-Biedl Syndrome
- Rare disease patient identification and genetic testing support programs
Is RYTM a Good Stock to Buy?
UQS Score rates RYTM as Below Average overall.
The Growth pillar stands out as the clearest positive — Rhythm is expanding its commercial footprint with IMCIVREE while advancing a pipeline that could meaningfully broaden its patient reach. The Risk pillar also registers as Good, reflecting a manageable near-term risk profile relative to many early-stage biotechs.
Quality and Moat both score Weak, pointing to limited profitability and a competitive positioning that has yet to be firmly established. Valuation is rated Elevated, suggesting the market may already be pricing in considerable future success.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does RYTM pay dividends?
No — Rhythm Pharmaceuticals, Inc. does not currently pay a dividend.
Rhythm Pharmaceuticals does not currently pay a dividend. This is typical for commercial-stage biopharmaceutical companies, where available capital is directed toward clinical development, commercialization of approved products, and pipeline expansion rather than shareholder distributions.
When does RYTM report earnings?
Rhythm Pharmaceuticals reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Revenue trends have been shaped by the ongoing commercial launch of IMCIVREE and the pace of patient identification in rare-disease markets. Operating expenses remain elevated as the company invests in both commercialization and clinical programs.
For the most recent quarter's results, visit Rhythm Pharmaceuticals' investor relations page directly.
RYTM Price History
+333.0% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Rhythm Pharmaceuticals, Inc.?
Based on Rhythm Pharmaceuticals, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
RYTM Long-term Outlook
The Growth pillar's Strong rating reflects a trajectory tied to expanding IMCIVREE's approved indications and advancing setmelanotide through later-stage trials. If pipeline milestones are met, the addressable patient population could grow considerably. However, the Elevated Valuation pillar signals that much of this optimism may already be reflected in the current share price, leaving limited margin for execution shortfalls. The Good Risk rating provides some reassurance, but Weak Quality and Moat scores are reminders that durable profitability and competitive defensibility remain works in progress.
Growth drivers
- Expanding IMCIVREE into additional rare genetic obesity indications
- Setmelanotide pipeline progression across multiple MC4R-pathway disorders
- Growing rare-disease patient identification infrastructure
Key risks
- Elevated valuation leaves little room for clinical or commercial setbacks
- Weak Quality pillar reflects ongoing profitability challenges
- Small, hard-to-identify patient populations can slow commercial uptake
RYTM vs Peers
Rhythm Pharmaceuticals operates in a niche corner of rare-disease biopharma, where a handful of focused companies compete for patients, capital, and clinical credibility.
Cogent focuses on precision therapies for genomically defined cancers, targeting a distinct rare-disease niche from Rhythm's obesity-pathway approach.
PTC Therapeutics has a broader rare-disease portfolio spanning neurological and metabolic conditions, giving it a more diversified commercial base than Rhythm.
Caris Life Sciences operates at the intersection of molecular diagnostics and precision oncology, differentiating itself through data-driven patient profiling rather than therapeutic development.
Frequently Asked Questions
What does Rhythm Pharmaceuticals do?
Rhythm Pharmaceuticals develops treatments for rare genetic diseases of obesity. Its commercial product, IMCIVREE, targets the melanocortin-4 receptor pathway to address specific inherited conditions that cause severe obesity. The company is also advancing a pipeline of therapies for related genetic disorders through clinical trials.
Does RYTM pay dividends?
No, Rhythm Pharmaceuticals does not pay a dividend. As a commercial-stage biopharmaceutical company, it reinvests available capital into product commercialization and clinical development rather than returning cash to shareholders through distributions.
When does RYTM report earnings?
Rhythm Pharmaceuticals follows a standard quarterly earnings cadence for US-listed companies. For the most current schedule and recent results, check the investor relations section of the company's official website.
Is RYTM a good stock to buy?
UQS Score rates RYTM as Below Average overall. The Growth pillar is Strong and Risk is Good, but Quality and Moat are both Weak, and Valuation is Elevated. Investors should weigh the pipeline opportunity against the current pricing and profitability challenges. The full pillar breakdown is available to Pro members.
Is RYTM overvalued?
The UQS Valuation pillar for RYTM is rated Elevated, suggesting the stock may be pricing in a significant amount of future success. This is common for rare-disease biotechs with approved products and active pipelines, but it does reduce the margin of safety if execution falls short.
How does RYTM compare to its competitors?
Rhythm Pharmaceuticals occupies a narrow niche — rare genetic obesity — that distinguishes it from peers like PTC Therapeutics, which has a broader rare-disease portfolio, and Cogent Biosciences, which focuses on precision oncology. Each company targets different patient populations and disease mechanisms within the broader rare-disease space.
What is RYTM's market cap bracket?
Rhythm Pharmaceuticals is classified as a mid-cap company. This places it in a range where it has meaningful commercial operations but still carries the development-stage risk profile typical of focused biopharmaceutical businesses.
Who founded Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals was founded in 2008, originally operating under the name Rhythm Metabolic, Inc. before rebranding in October 2015. Details on the founding team are publicly available through the company's official filings and corporate history.
Is RYTM a long-term quality investment?
From a long-term quality perspective, RYTM's UQS profile presents a mixed picture. Strong Growth and Good Risk are encouraging indicators, but Weak Quality and Moat scores suggest the company has not yet built the durable profitability or competitive defensibility that typically characterize high-quality long-term holdings. Pro members can view the complete analysis.
What is the main competitive advantage of Rhythm Pharmaceuticals?
Rhythm's primary advantage lies in its focus on the melanocortin-4 receptor pathway and its first-mover position in approved treatments for specific rare genetic obesity conditions. However, the UQS Moat pillar is rated Weak, indicating this advantage has not yet translated into a firmly defensible competitive position.
What sector does RYTM belong to?
Rhythm Pharmaceuticals belongs to the Healthcare sector, specifically within the biopharmaceutical industry. It focuses on rare genetic diseases, a sub-segment characterized by smaller patient populations, specialized treatment approaches, and often significant pricing power for approved therapies.
Is RYTM a growth stock or value stock?
Based on its UQS profile, RYTM leans toward the growth category — the Growth pillar is rated Strong, reflecting pipeline expansion and commercial momentum. The Valuation pillar is Elevated, which is more consistent with a growth-oriented stock than a value opportunity at current levels.
Unlock Full RYTM Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access detailed financial metrics and trend data
- ✓Compare RYTM against sector peers side by side
- ✓See the complete Quality and Moat breakdown
- ✓Track valuation changes over time with Pro tools
- ✓Get the full analyst-grade view in one place
Pro Analysis
RYTM — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 9, 2026 | 41.1 | 14.6 | 35.0 | 97.9 | 60.9 | 0.0 | -0.2 |
| Apr 2, 2026 | 41.3 | 14.6 | 35.0 | 97.9 | 62.0 | 0.0 | — |
RYTM — Pillar Breakdown
Quality
— 14.6/100 (25%)Rhythm Pharmaceuticals, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 97.9/100 (20%)Rhythm Pharmaceuticals, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 60.9/100 (15%)Rhythm Pharmaceuticals, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Rhythm Pharmaceuticals, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 35/100 (25%)Rhythm Pharmaceuticals, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for RYTM.
Score Composition
Financial Data
More Stock Analysis
How is the RYTM UQS Score Calculated?
The UQS (Unified Quality Score) for Rhythm Pharmaceuticals, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Rhythm Pharmaceuticals, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Rhythm Pharmaceuticals, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.